Zobrazeno 1 - 10 of 61 pro vyhledávání: '"Hans Klaus Breddin"'
1
Cardiopulmonary effects and safety of prostaglandin E1: A review
Autor: Hans Klaus Breddin, Gottfried Rudofsky, Heinz Heidrich, Peter Scheffler
Publikováno v: International Journal of Angiology. 3:160-168
Intraarterial and intravenous infusion of prostaglandin E1 (PGE1) is established treatment for severe peripheral arterial occlusive disease, particularly in Europe and Japan. In this critical appraisal, experimental and clinical studies are reviewed,
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e14c1d777c5fcfed57642aa3946e4b0b
https://doi.org/10.1007/bf02014937
Zobrazit plný text záznamu
2
Effects of the Oral, Direct Factor Xa Inhibitor Rivaroxaban on Platelet-Induced Thrombin Generation and Prothrombinase Activity1
Autor: Nils von Hentig, Michael Becka, Jochen Graff, Hans-Klaus Breddin, Sebastian Harder, Frank Misselwitz, Dagmar Kubitza
Publikováno v: The Journal of Clinical Pharmacology. 47:1398-1407
Rivaroxaban (BAY 59-7939) is an oral, direct factor Xa inhibitor in advanced development. This study was undertaken to investigate its effects on thrombin generation. In this placebo-controlled, randomized, crossover study, 12 healthy subjects receiv
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::85ad6748d7774e963f3e899dbc419bbc
https://doi.org/10.1177/0091270007302952
Zobrazit plný text záznamu
4
Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time, and Ecarin Clotting Time
Autor: Jochen Graff, Hikari Watanabe, Sebastian Harder, Hans-Klaus Breddin, Ute Klinkhardt, Jeanine M. Walenga, Masanori Osakabe, Nils von Hentig
Publikováno v: Thrombosis and Haemostasis. 91:1137-1145
SummaryTreatment with the direct thrombin inhibitor argatroban (ARG) is often followed by vitamin K-antagonist treatment (VKA). Phenprocoumon (PC) and acenocoumarol (AC) are frequently used in Europe. The standard monitoring test for VKA, prothrombin
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd09940ad6055eeda8f707770d10c8b5
https://doi.org/10.1160/th03-12-0794
Zobrazit plný text záznamu
5
Acetylsalicylic acid tablets with glycine improve long-term tolerability in antiplatelet drug therapy
Autor: Jutta Haselmann, Werner Kusche, Ulrich Schwantes, Hans Klaus Breddin, Rafaela Paxinos
Publikováno v: Advances in Therapy. 20:237-245
To determine the tolerability of a glycine (Gly)-containing acetylsalicylic acid (ASA) preparation (Gly-ASA), investigators selected 1135 patients already receiving longterm antiplatelet therapy for a noninterventional trial of Gly-ASA 50 to 300 mg d
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8f147ad003b5533882f2d650fa75b05
https://doi.org/10.1007/bf02849852
Zobrazit plný text záznamu
6
Pharmacodynamic characterization of the interaction between the glycoprotein IIb/IIIa inhibitor YM337 and unfractionated heparin and aspirin in humans
Autor: Jochen Graff, Ute Klinkhardt, Dagmar Westrup, Sebastian Harder, Hans Klaus Breddin, Carl M. Kirchmaier
Publikováno v: British Journal of Clinical Pharmacology. 56:321-326
Aims To investigate the pharmacodynamic interaction of unfractionated heparin (UFH) and acetylic salicylic acid (ASA) on YM337, a monoclonal humanized antibody of the platelet GPIIb/IIIa receptor. Methods In a randomized, placebo-controlled study thr
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::13dc7c26e9fc734b1210a3bf5f8bde8a
https://doi.org/10.1046/j.0306-5251.2003.01873.x
Zobrazit plný text záznamu
7
Effects of PEG-Hirudin in Clotting Parameters and Platelet Function and its Interaction with Aspirin in Healthy Volunteers
Autor: Piotr Radziwon, Hans Klaus Breddin, Hans-Ulrich Esslinger, Stephan Köhne, Jeanine M. Walenga
Publikováno v: Clinical and Applied Thrombosis/Hemostasis. 9:79-88
The purpose of this study was to investigate the pharmacodynamics of PEG-Hirudin and its potential interactions with acetylsalicylic acid (ASA 325 mg once daily from days 1-3). In a randomized, 2-way cross-over trial, 6 healthy volunteers received PE
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac603d38de06fe93244ea85494412290
https://doi.org/10.1177/107602960300900111
Zobrazit plný text záznamu
8
Incidence and clinical relevance of heparin-induced antibodies in patients with deep vein thrombosis treated with unfractionated or low-molecular-weight heparin
Autor: Rupert Bauersachs, Roumen Nakov, Frank Misselwitz, Edelgard Lindhoff-Last, Hans-Klaus Breddin
Publikováno v: British Journal of Haematology. 118:1137-1142
Summary. The frequency of heparin-induced thrombocytopenia (HIT) varies between different clinical treatment settings and remains unknown for patients treated with unfractionated (UFH) or low-molecular-weight heparin (LMWH) because of deep vein throm
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5061352b8cc29cfa475d05a944708950
https://doi.org/10.1046/j.1365-2141.2002.03687.x
Zobrazit plný text záznamu
9
Reviparin sodium – a new low molecular weight heparin
Autor: Hans Klaus Breddin
Publikováno v: Expert Opinion on Pharmacotherapy. 3:173-182
Reviparin sodium (Clivarine), Knoll AG) is a low molecular weight heparin (LMWH) with a mean peak molecular weight of 3900 Da. It is characterised by a narrow molecular weight distribution profile, with an anti-factor Xa (anti-Xa):anti-factor IIa (an
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3608e61e600ecbd34a5f4cdc751dae16
https://doi.org/10.1517/14656566.3.2.173
Zobrazit plný text záznamu
10
Pharmacodynamic characterization of the interaction between abciximab or tirofiban with unfractionated or a low molecular weight heparin in healthy subjects
Autor: Ute Klinkhardt, Carl M. Kirchmaier, Hans Klaus Breddin, Dagmar Westrup, Sebastian Harder, Hans-Ulrich Esslinger, Jochen Graff
Publikováno v: British Journal of Clinical Pharmacology. 52:297-305
Aims The objective of our study was to define the interaction between either unfractionated heparin (UFH) or a low molecular weight heparin, reviparin (REV), and the pharmacodynamic profile of the GPIIb/IIIa-antagonists abciximab (ABC) or tirofiban (
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d2da2bb0d058dd4f944dca3f21fc60ab
https://doi.org/10.1046/j.0306-5251.2001.01446.x
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje